1 |
48 |
F |
Mass/GIST/NET |
Mid body |
36 × 22 |
SF, LP, OP, IgG4 + 210/hpf, IgG4/IgG ratio about 85% |
NA |
WR |
Woo et al. [3] |
2 |
62 |
F |
Mass/gastic cancer |
Antrum |
80 × 30 |
SF, LP, OP, IgG4 + ve lymphoplasmacytes > 50/hpf |
Elevated |
DG |
Bulanov et al. [6] |
3 |
59 |
F |
Mass/GIST |
NA |
33 × 14 |
Abundant LP, SF, lymphoid follicles, IgG4 > 50/hpf |
Normal |
WR |
Kim et al. [7] |
4 |
56 |
F |
Mass/GIST |
NA |
21 × 15 |
Abundant LP, SF, calcification, IgG4 > 50/hpf |
Normal |
WR |
Kim et al. [7] |
5 |
60 |
F |
Nodule/NA |
Fundus |
10 × 15 |
Fibrosis, dense LP, IgG4 > 80/hpf |
Normal |
WR |
Chetty et al. [8] |
6 |
45 |
M |
Multiple nodules/NA |
Antrum |
Up to 22 |
LP, many eosinophils, IgG4/IgG ratio 0.84 |
NA |
DG |
Chetty et al. [8] |
7 |
56 |
M |
Nodule/NA |
Body |
8 |
SF, LP, IgG4-40-102/hpf IgG4/IgG ratio 80%–90% |
NA |
ESR |
Na et al. [9] |
8 |
58 |
M |
Nodule/AIP |
Fundus and body |
14 |
Dense LP, extensive IgG and IgG4 + staining |
Normal |
Steroid |
Baez et al. [10] |
9 |
55 |
F |
Nodule/GIST |
Body |
20 |
Dense hyalinization, LP, IgG4/IgG ratio 41% |
Normal |
ESR |
Zhang et al. [11] |
10 |
75 |
F |
Polyp/GIST |
Body |
56 × 50 |
Fibrosis, LP, many eosinophils, IgG4–39/hpf |
Normal |
WR |
Rollins et al. [12] |
11 |
44 |
M |
Mass/GIST |
Body |
20 × 18 |
Fibrosis, LP, IgG4 + ve lymphoplasmacytes |
Normal |
ESR |
Otsuka et al. [13] |
12 |
27 |
F |
Mass/GIST/NET |
Fundus |
40 |
Dense fibrosis, LP, IgG4/IgG ratio 25.3% |
Normal |
WR |
Cheong et al. [14] |
13 |
29 |
F |
Mass/GIST |
Body |
20 × 15 |
Fibrosis, LP, IgG4 + ve plasma cells 150/hpf |
NA |
WR |
Skorus et al. [15] |
14 |
43 |
M |
Mass/GIST |
Antrum |
70 × 50 |
Dense LP, IgG4 + plasma cells 35–40/hpf |
Elevated |
WR + Steroids |
Present case 1 |
15 |
58 |
M |
Mass/GIST |
Distal body |
45 × 40 |
LP, SP, IgG4 + ve plasma cells 20–30/hpf |
Elevated |
WR |
Present case 2 |